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RESEARCH ARTICLE

A Caenorhabditis elegans behavioral assay distinguishes early
stage prostate cancer patient urine from controls

ABSTRACT
Current methods for non-invasive prostate cancer (PrCa) detection
have a high false-positive rate and often result in unnecessary
biopsies. Previous work has suggested that urinary volatile organic
compound (VOC) biomarkers may be able to distinguish PrCa cases
from benign disease. The behavior of the nematode Caenorhabditis
elegans has been proposed as a tool to take advantage of these
potential VOC profiles. To test the ability of C. elegans Bristol N2 to
distinguish PrCa cases from controls, we performed chemotaxis
assays using human urine samples collected from men screened for
PrCa. Behavioral response of nematodes towards diluted urine from
PrCa cases was compared to response to samples from cancer-free
controls. Overall, we observed a significant attraction of young adultstage C. elegans nematodes to 1:100 diluted urine from confirmed
PrCa cases and repulsion of C. elegans to urine from controls. When
C. elegans chemotaxis index was considered alongside prostatespecific antigen levels for distinguishing cancer from cancer-free
controls, the accuracy of patient classification was 81%. We also
observed behavioral attraction of C. elegans to two previously
reported VOCs to be increased in PrCa patient urine. We conclude
nematode behavior distinguishes PrCa case urine from controls in a
dilution-dependent manner.
KEY WORDS: Caenorhabditis elegans, Nematode, Olfaction, Liquid
biopsy, Prostate cancer, Volatile organic compounds

INTRODUCTION

Many cancers have altered metabolic pathways that support, or may
even cause, malignancy (Ward and Thompson, 2012). Detection of
these cancer-related metabolites or volatile compounds in blood and
urine would provide an ideal means of non-invasive early
cancer detection. Yet, brute-force chemical analyses have been
unsuccessful in determining metabolite profiles that consistently
distinguish early cancer from healthy biofluids (Liesenfeld et al.,
2013). Remarkably, even in the early stages of malignancy, there is
evidence that cancer patients emit odors that can be accurately
detected by canine and murine olfaction (Lippi and Cervellin, 2012;
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Sato et al., 2017; Edwards et al., 2017; Fischer-Tenhagen et al.,
2018; Elliker et al., 2014). Replicating this process of scent
identification in mammals using technology or computation is
hindered by the exceptionally complex neural processing in
mammals that occurs to identify unique odors (Mori and Sakano,
2011). Further, mammalian detection systems rely on training and
learned memory to discriminate between odors, and efficacy may be
affected by animal personality, genetics, or environment (Elliker
et al., 2014). Therefore, animal systems that have a naturally
occurring odor discrimination for cancer patient samples could be a
powerful tool for developing early cancer detection technology.
Recent work by Hirotsu et al. (2015) demonstrated the feasibility
of a nematode scent detection test (NSDT) to take advantage of the
chemosensory abilities of Caenorhabditis elegans, a small
nematode worm. C. elegans is commonly used as an experimental
model in neurobiology because of its simple nervous system, which
is primarily devoted to chemosensation (Bargmann, 2006). In
addition, with a sizable fraction of its genome being dedicated
specifically to olfactory components, the availability of genomic
tools makes C. elegans an appealing system for understanding
sensory mechanisms (Boulin and Hobert, 2012). C. elegans has a
well-documented ability to detect a wide variety of volatile and
water-soluble compounds necessary to differentiate food, mates,
pathogens and predators encountered in its natural environment
(Bargmann, 2006; Bargmann et al., 1993). Using a simple assay
setup, Hirotsu et al. (2015) demonstrated that C. elegans can detect
multiple types of cancer, and potentially even pre-cancer, from 1:10
diluted urine with >95% specificity and sensitivity. This assay,
known as a chemotaxis assay, is a commonly performed lab assay
and has been used to score the relative attractiveness or
repulsiveness of various volatile organic compounds (VOCs) to
live C. elegans nematodes (Bargmann et al., 1993; Margie et al.,
2013; Yoshida et al., 2012). Hirotsu et al. (2015) further showed that
the C. elegans behavioral response worked strictly through
G-protein coupled receptor (GPCR) mediated signaling and via
chemosensory neurons known to be important for sensing VOCs.
More recently and using a similar chemotaxis assay, a report by
Kusumoto et al. (2020) demonstrated that C. elegans accurately
differentiates between matched preoperative and postoperative
samples from patients that underwent gastrointestinal cancer
resection. Thus, the natural behavioral response of C. elegans to
cancer patient urine may provide a useful tool for detecting cancer
VOCs at early, treatable stages or for monitoring residual disease.
However, the extent to which this behavioral response can
effectively distinguish malignant samples from benign disease
remains to be determined.
In this work, we apply a version of the NSDT to urine samples
from patients with prostate cancer (PrCa) and compare the
behavioral response to benign controls. We hypothesized that
differentially abundant VOCs present in PrCa urine samples causes
1
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an attractive behavioral response in C. elegans that can distinguish
them from control urine samples. The current gold-standard
biomarker for non-invasive PrCa detection is prostate-specific
antigen (PSA), which has high sensitivity but is known to suffer
from low specificity (Thompson et al., 2004; Mistry and Cable,
2003). PSA is excreted by both malignant as well as nonmalignant
epithelial cells and can therefore be present in the serum of patients
with benign diseases such as prostatitis and prostatic hyperplasia
(Eastham, 2017). Because overdiagnosis of PrCa often leads to
invasive and risky needle biopsies (Loeb et al., 2011), biomarkers
that can supplement or replace PSA are highly desired. Our findings
suggest there are VOC profiles in cancer-patient urine that can
distinguish early stage PrCa from control urine. This behavioral
classification method appeared to be dilution dependent and yielded
results that support this unique tool for developing high-throughput,
non-invasive early detection screens.
RESULTS
Cohort clinical features

There was no significant difference among sample group means for
body mass index (BMI), age at collection, or tobacco use (Table 1).
Average PSA levels were determined to be significantly different
among the groups (Kruskal–Wallis rank sum test, P<0.001) such
that cancer and benign individuals had, on average, higher PSA than
negative screen samples. Prostate size was nearly significantly
different among groups (Kruskal–Wallis rank sum test, P=0.058)
such that benign individuals tended to have an average larger
prostate size than cancer or negative screen samples.
C. elegans N2 are attracted to previously identified VOC
candidates for PrCa classification

To determine if C. elegans N2 displayed a behavioral response to
candidate VOCs, chemotaxis assays were performed using diluted
2-octonone or pentanal as test samples. C. elegans N2 demonstrated
overall attraction to 2-octonone at 64 mM and 640 mM (Fig. 1, left).
For pentanal, C. elegans N2 demonstrated attraction, but only at the
highest concentration of 940 mM (Fig. 1, right).

C. elegans N2 nematodes demonstrate dilution-dependent
behavioral response to patient urine samples

Among the five dilutions measured for chemotaxis index (CI), we
observed a dilution of 1:100 to yield the best discrimination of
cancer patient urine from controls in preliminary assays as defined
by number of samples with overall behavioral attraction (CI >0)
towards cancer samples and repulsion (CI <0) from controls (Fig. 2,
left). We consistently observed high CI values in the isoamyl
alcohol positive control assays (Fig. 2, right). The 1:100 urine
dilution was used for all subsequent chemotaxis assays on patient
samples.
C. elegans N2 nematodes demonstrate an overall attraction
to PrCa patient urine compared to controls

All chemotaxis assays had at least six replicates performed except
for individuals N03, B04 and C02, which had four each. The
average number of worms that chemotaxed in each assay for
negative screen, benign and cancer groups was 37.4 (s.e.m.=1.7), 38
(s.e.m.=1.7) and 34 (s.e.m.=1.3), respectively. We observed both
attractive and repulsive patient urine samples within the three groups
(Fig. 3). After CIs for each patient were averaged, urine from PrCa
patients elicited generally positive average CIs compared to urine
from benign and negative screen individuals (Fig. 4). Shapiro–Wilk
normality test results indicated the distribution of measured CIs
did not significantly differ from a normal distribution for negative
screen (P=0.45), benign (P=0.91) or cancer (P=0.95) groups. Oneway statistical analysis revealed a significant difference in means
among the three groups (one-way analysis of variance, ANOVA,
Fd.f.=2=4.71, P=0.012). A Tukey’s honestly significant difference
(HSD) post-hoc test indicated that average CIs for PrCa were
significantly higher than those of benign (P=0.020) and negative
screen (P=0.034), while benign and negative screen types were not
significantly different (P=0.896). We found that PrCa urine
samples CIs were significantly higher compared to benign and
negative screen individuals when all technical replicates (i.e. no
subsampling) were considered for each patient sample (one-way
ANOVA, Fd.f.=2=4.71, P=0.0045, Fig. S1).

Table 1. Table of cohort clinical features separated by group
Cancer (n=21)

Benign (n=19)

Neg Screen (n=27)

Total (n=67)

28.1 (3.39)
22.0-34.4

28.5 (4.44)
23.1-38.2

28.3 (4.46)
20.0-39.0

28.3 (4.09)
20.0-39.0

7.62 (3.66)
3.95-16.5

7.18 (3.52)
1.64-14.21

5
1.79 (1.65)
0.170-6.97

5
5.42 (4.04)
0.170-16.5

65.2 (4.49)
57-74

62.6 (7.26)
47-75

65.4 (5.33)
54-74

64.6 (5.76)
47-75

2
41.1 (21.3)
16-112

2
55.6 (22.6)
25-97

10
40.7 (17.5)
15-85

14
45.5 (21.3)
15-112

12 (57.1%)
9 (42.9%)

13 (68.4%)
6 (31.6%)

1
16 (61.5%)
10 (38.5%)

1
41 (62.1%)
25 (37.9%)

a

0.984

<0.001

0.224

0.058

0.761
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BMI
Mean (s.d.)
Range
PSAb
Missing
Mean (s.d.)
Range
Age at Collectionc
Mean (s.d.)
Range
Prostate Sized
Missing
Mean (s.d.)
Range
Tobacco Usee
Missing
No
Yes

P-value

a

Body mass index in kg/m2; Kruskal–Wallis rank sum test.
Prostate-specific antigen in ng/ml; Kruskal–Wallis rank sum test.
c
Age at sample collection in years; one-way ANOVA analysis.
d
Prostate size in cm3; Kruskal–Wallis rank sum test.
e
Tobacco use status where ‘yes’ includes current and former smokers; Pearson’s Chi-square test.
s.d., standard deviation.
b
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Fig. 1. C. elegans N2 are attracted
to two VOCs that were previously
reported to be increased in
prostate cancer patient urine
compared to healthy controls.
Chemotaxis assays were performed
using 2-octonone (left) or pentanal
(right) diluted with water.
n=6 chemotaxis assays per
concentration; error bars represent
mean±s.e.m..

We assessed potential pairwise associations between average CIs
and PSA, BMI, age at collection, and prostate size. C. elegans N2
CIs did not correlate significantly with PSA, BMI, or age (Fig. 5).
We also found no difference in average CIs between current/former
smokers (n=25) and non-smokers (n=41) (Welch’s two-sample
t-test, P=0.81; Fig. S2, left). Similarly, we found no significant
difference in the average CIs of low (3+3 or 3+4, n=13) and high
(≥4+3, n=8) Gleason score tumors (Welch’s two-sample t-test,
P=0.23) within the PrCa group (Fig. S2, right).
Classification model performance of CI alone, PSA alone,
and combined

To calculate sensitivity and specificity, we used classification as
determined by pathology. True positives were considered to be
individuals with a confirmed case of PrCa following biopsy, while
true negatives were considered to be individuals who either had a
negative biopsy or were deemed to not have PrCa following screening.
To test the ability of average C. elegans N2 CIs to predict cancer
status, we used a model using CI >0 to classify cancer and CI <0 to
classify cancer free. With this CI model, a sensitivity of 76% and a
specificity of 67% was determined for discriminating PrCa patient
urine from controls. In comparison, using PSA values at the standard
threshold of ≥4 ng/ml for PrCa classification yielded a sensitivity
and specificity of 95% and 59%, respectively. The overall accuracy
of CI for classifying PrCa versus controls was 70% (balanced
accuracy=72%), slightly lower than the 71% accuracy of PSA alone
(balanced accuracy=77%). Neither CI nor PSA alone were determined
to have a significantly higher accuracy than the no-information rate
(NIR). In addition, both CI and PSA classification models alone were
determined to have significant Mcnemar’s test P-values, and therefore
both models are presumed to be fundamentally different from the
classifications made by pathological assessment.
We next tested a combined classification model that required both
CI >0 and PSA ≥4 ng/ml for a PrCa diagnosis and compared the

model to using CI or PSA alone. Using the combined model, we
were able to increase the specificity to 85% at the cost of reducing
the sensitivity to 71%. The combined model accuracy improved to
81% (balanced accuracy 78%). In addition, the combined model
had significantly better accuracy than the NIR of 66% (P=9e-3).
Classification model performance comparisons are summarized in
Table 2.
DISCUSSION

Accumulating evidence suggests that the metabolomic profiles of
patients with prostate cancer can be distinguished from normal
patients and this difference could potentially be measured through
blood or urine samples (Kdadra et al., 2019). The leading metabolite
candidate for prostate cancer, sarcosine, has remained controversial
as a specific urinary biomarker and has yet to find widespread
adoption in the clinic (Sreekumar et al., 2009; Wang et al., 2018;
Lima et al., 2016). Thus, the search for alternative methods of
cancer metabolite biomarker discovery continues to be of great
interest.
The potential for animals to sense malignancy has received
increasing attention since the phenomenon was first described over
three decades ago (Williams and Pembroke, 1989). Since the first
report of C. elegans accurately classifying cancer samples by
Hirotsu et al. (2015), similar methods have been applied using
C. elegans to detect sepsis (Tee et al., 2019) and tuberculosisspecific odorants (Neto et al., 2016). Two of the VOCs proposed to
be increased in PrCa urine samples by Khalid et al. (2015) were
found to elicit behavioral attraction of C. elegans under our assay
conditions. When chemotaxis assays were performed using urine
samples from our cohort, our overall findings agree with the
previous work by Hirotsu et al. (2015) and support a dilutiondependent behavioral response of C. elegans nematodes to cancer
patient and control urine. It should also be noted that only one
identified case of PrCa was tested in the Hirotsu et al. (2015) cohort,
and thus direct comparisons of results are difficult. Interestingly,
some urine dilutions elicited opposite behavioral responses
3
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(i.e. switching from attractive to repulsive) compared to other
dilutions of the same sample. This finding was also observed by
Hirotsu et al. (2015) and may be due to the complex VOC
composition of human urine (Bouatra et al., 2013) causing
concentration-dependent preference changes as dilutions change
(Yoshida et al., 2012). Prior work by Cornu et al. (2011) reported
91% sensitivity and specificity using canine olfaction trained
exclusively on urine samples from prostate cancer patients and
controls. The Cornu et al. (2011) sample cohort included 33 urine
samples from confirmed stages I–IV prostate cancer cases and 33
control samples from patients with negative biopsies. Our results
also suggested significant olfactory discrimination of C. elegans to
prostate cancer patient urine compared to control patients, although
our observed sensitivity and specificity was lower than the results
reported by Cornu et al. (2011). This reduced performance may be
due in part to our cohort consisting of only early stage (stages I–II)
prostate cancer samples. It is possible that there is an increase in the
amount or composition of attractive VOCs as prostate cancer
progresses (Kdadra et al., 2019). Our data do not indicate a clear
preference by C. elegans for low (3+3 or 3+4) or high (≥4+3)
Gleason score tumors, and the overall effect of tumor stage on
animal olfaction remains to be determined.
Interestingly, our accuracy of 66% using the C. elegans CI for
patient classification is within the range of the ∼66% accuracy
reported by Khalid et al. (2015) using four VOCs. Whether any of
those four VOCs are the same ones the nematodes detect in the PrCa

urine samples of our cohort is unknown. Importantly, it is possible
that the utility of VOCs alone in PrCa urine sample classification is
limited as a biomarker. This limitation could be due to tumor
heterogeneity, wherein only some prostate adenocarcinomas
produce the identifying VOC(s), or high among-individual
variation in VOC expression that can mask signal. Importantly,
however, our data suggest that the C. elegans CI in response to urine
samples is independent of blood-derived PSA and combining the
two measurements increased the accuracy of the classification
model to 81%. A similar finding was reported by Khalid et al.
(2015) and later by Gao et al. (2019) whereby the sensitivity and
specificity of PrCa VOC profiling by GC-MS was significantly
improved by also using PSA. Thus, our study further supports
supplementing PSA models with VOC profiles as a means to
increase the accuracy of PrCa detection.
Because knowledge of the specific ligand-GPCR interactions
that determine C. elegans chemotactic behavior remains limited
(Bargmann, 2006; Tobin, 2008; Vidal et al., 2018), the exact
olfactory receptors that may be responsible for C. elegans behaviorbased cancer detection are unknown. Regardless of this limitation,
there are approaches that could be further developed to leverage
C. elegans olfaction as a diagnostic or biomarker discovery tool.
The first approach is to develop high-throughput and reproducible
technology that can use the animal behavior preference itself as a
diagnostic assay (e.g. the ‘N-nose’ demonstrated by Hirotsu et al.,
2015 and Kusumoto et al., 2020). Another possibility is to use the
4
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Fig. 2. C. elegans N2 showed
highest average attraction to
1:100 diluted PrCa patient urine
compared to 1:10, 1:50, 1:500, and
1:1000 dilutions. The same urine
samples are represented across the
five dilutions. Each of the three
sample groups (negative screen,
benign, and cancer) comprises four
independent urine samples for which
four to six technical replicate
chemotaxis assays were performed.
Data points represent the average of
CI associated with each patient
sample. Typical chemotaxis assay
results when using 9.09 mM isoamyl
alcohol as a positive control are
shown on far right (n=6 assays).
Error bars represent mean±s.e.m..
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Fig. 3. Chemotaxis assay CIs
obtained from individual patient
urine sample technical replicates
at 1:100 dilution. Each bar
represents average C. elegans N2
CIs in response to an individual
patient urine sample for which four
to six technical replicate chemotaxis
assays were conducted. Error bars
represent mean±s.e.m..

MATERIALS AND METHODS
Subject inclusion criteria and urine sample collection

All experimental protocols were reviewed and approved by the Oregon
Health and Science University Institutional Review Board ( protocol number
18048). Informed consent was obtained from all patients included in this
study. Urine from human subjects was acquired based on the following
inclusion criteria: (1) male patients between 45–75 years old at time of
consent, (2) no current or previous cancer diagnosis (excluding squamous
cell/basal cell carcinoma), (3) a total PSA between 2.5–20 ng/ml drawn
within the last 2 years, (4) no more than one previous negative biopsy, (5) no
prostate MRI with Pi-RADS four or five lesions, (6) no digital rectal exam
(DRE) score of cT3/4 (bilateral nodules), and (7) no history of prostate
intervention within the last 6 months. Patient urine samples were collected at
the Oregon Health and Science University and Portland Veterans Affairs
Medical Center urology clinics. Urine samples were collected uniformly in
preservative-free collection cups, transported at 4°C, and stored at -80°C.
All urine samples were collected post-DRE and prior to any biopsy or
surgical resection (if applicable). The cohort included urine samples from
PrCa cases, control benign patients, and control negative screen patients. For
each patient, we received one urine sample and therefore define each urine
sample as a separate biological replicate. For the PrCa urine samples,
patients were confirmed to have prostate adenocarcinoma (stage I or II) by a
pathologist following biopsy and/or surgical resection. Gleason scores were
also determined for positive PrCa cases. We categorized Gleason scores as
having either low (Gleason score 3+3 or 3+4) or high (Gleason score ≥4+3)
probability of postoperative progression (Chan et al., 2000). For benign
urine samples, patients were suspected to have prostate carcinoma, but
biopsy results did not have evidence for carcinoma. Patients with benign
diagnosis may have had other pathologies or atypical results that are not
cancer. For negative screen urine samples, patients presented urinary tract
symptoms or were undergoing routine screening, but following screening
examination and DRE, a prostate biopsy or fine-needle aspiration was
deemed not necessary and was therefore not performed. The final study
cohort included 21 urine samples from confirmed PrCa cases, 19 urine
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behavioral assay as an unbiased sensor system that could be coupled
with a discovery method such as GC-MS. In this method, the
behavioral assay has a similar function to an ‘electronic nose’, but
with a potentially increased limit of detection and no need for
machine learning (de Boer et al., 2014). A previous study in the
moth Manduca sexta recorded the neural responses of M. sexta to
identify complex odors of interest fractionated by GC (Riffell et al.,
2009). More recently, work by Trivedi et al. (2019) leveraged the
remarkable olfactory ability of a human ‘super smeller’ to annotate
GC-MS spectra for biomarker discovery in Parkinson’s disease
patient sebum, the lipid secretions of sebaceous glands in the skin.
Trivedi et al. (2019) concluded that VOC profiles in Parkinson’s
disease patient sebum could not be accurately distinguished from
normal controls when relying solely on unsupervised clustering.
Combined with the extensive repertoire of genetic and neural
biology tools available to the C. elegans model system, our data
support the possibility of using C. elegans olfaction for biomarker
discovery in highly heterogeneous diseases where among-sample
variation otherwise makes unsupervised learning difficult.
Biomarkers that can be obtained noninvasively and boost the
accuracy of PSA for PrCa detection are highly desired. In this work,
C. elegans demonstrated a weak but significant attraction to urine
from PrCa patients when measured by behavioral assay. The
C. elegans behavioral assay did not misclassify the same patients as
PSA and combining the two outcomes increased overall accuracy
and specificity. The potentially independent value of CI, and thus
potentially of VOCs of interest, was further supported by the lack of
CI correlation with other clinical attributes. While we were unable to
determine the VOCs that elicited the behavioral response, our
results support previous work that animal olfactory responses could
be a useful tool for cancer biomarker discovery.
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Fig. 4. C. elegans N2 are more
attracted to urine from PrCa
patients than to benign or
negative screen patient urine.
Chemotaxis assay technical
replicates (n=4–6 assays per
individual patient urine sample)
were averaged for negative screen
(n=27 individuals), benign (n=19
individuals), and cancer (n=21
individuals) patient urine samples
prior to plotting and statistical
testing. Boxplots for each group are
inset within their respective violin
plots. Dots above or below boxplots
are potential outliers. Statistically
different means between groups are
shown with *, one-way ANOVA and
Tukey’s HSD post-hoc test, P<0.05.

Nematode strains and culture conditions

C. elegans Bristol N2 (referred to as ‘N2’) was used for all chemotaxis
assays. C. elegans N2, a commonly used lab strain, has experienced many
generations of lab culture before being cryogenically stored as separate strain
in 1980 (WormBase). Following Hirotsu et al. (2015), nematodes were
maintained at 20°C on Nematode Growth Medium Lite (NGML; US
Biological, N1005) plates seeded with a lawn of NA22 Escherichia coli as a
food source.
Nematode age synchronization

Prior to all experiments, strains were allowed to recover from freezing for
two to three generations prior to use. In accordance with Hirotsu et al.
(2015), young adult stage nematodes were used for all chemotaxis assays.
All centrifugation steps were performed at room temperature (i.e. 21°C).
Mixed-age nematode populations were age synchronized using standard
bleach methods (Stiernagle, 1999). The resulting egg pellet was then
resuspended into the 1 ml of remaining buffer solution and the egg–buffer
solution was pipetted onto new NGML plates seeded with NA22 E. coli.
The plated eggs were maintained at 20°C for 72 h to allow age-synchronized
nematodes to hatch and reach the young adult stage.
Chemotaxis assays and calculation of chemotaxis index

We used a chemotaxis assay plate format with diagonally opposing sample
quadrants to reduce the potential of random worm movements affecting
results. Following Margie et al. (2013), unseeded NGML plates prepared
without antibiotic were divided into four equally sized quadrants (Fig. 6).
A circle with a diameter of 1 cm was drawn around the center of the plate.
Quadrants across from one another were labelled with ‘T’ for the sample
( previously reported VOC or diluted urine) and the other two quadrants
were labelled ‘C’ for control diluent (water). Each quadrant contained a dot
2.5 cm from the center of the plate for placement of 1 µl of sample or water.

Approximately 50 washed, young adult nematodes were plated in the center
of the assay plate. We controlled for light by using clean, unscented towels
to cover the chemotaxis plates during assays. The plates were left on the
benchtop, covered with towels for 1 h at room temperature (21°C). Assays
were performed for 1 h at room temperature to match the length and
temperature conditions of the chemotaxis assays performed by Hirotsu et al.
(2015). After 1 h, the plates were individually photographed and the number
of nematodes in each quadrant was recorded. Each completed chemotaxis
assay was considered a technical replicate for statistical analysis. An
example completed chemotaxis assay is shown in Fig. S3.
To calculate an overall score of behavioral response to a sample, hereafter
referred to as the chemotaxis index (CI), the equation:
CI ¼ ½ðT1 þ T2 Þ  ðC1 þ C2 ÞÞ=ððT1 þ T2 þ C1 þ C2 Þ;

ð1Þ

was used where T1+T2 was the number of nematodes that migrated into the
first and second quadrants containing the sample being tested and C1+C2 is
the number of nematodes that migrated into the first and second quadrants
containing only water, respectively (Margie et al., 2013). To control for
nematodes that were immobile or incapable of olfaction, all animals in the
1 cm circle near the center were not counted. Thus, a positive CI when
calculated using Eqn 1 indicates nematode attraction towards a sample, a
negative CI indicates repulsion from a sample, and a CI=0 indicates no
behavioral preference. We define a technical replicate as a single completed
chemotaxis assay using one diluted sample. At least 4–6 technical replicates
were performed for each urine sample or VOC compound.
Chemotaxis assays on previously reported PrCa VOCs

CIs were obtained for two VOCs previously identified by Khalid et al.
(2015) to be potential biomarkers of PrCa. Chemotaxis assays were
performed using serial dilutions of 2-octonone (6.4 mM, 64 mM and
640 mM; Sigma-Aldrich 2479, analytical standard grade, ≥99.5%
purity) or pentanal (9.4 mM, 94 mM, 940 mM; Sigma-Aldrich 42272,
analytical standard grade, ≥97.5% purity). Six replicates of each
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samples from control benign patients, and 27 urine samples from control
negative screen patients (Table 1).
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Fig. 5. Pearson correlation coefficients
(r) comparing patient clinical features to
CI. Chemotaxis index, prostate size (cm3),
BMI (kg/m2), PSA (ng/ml), and age at urine
sample collection (years) for each patient
were compared. Histograms include a
kernel density estimation in red and rug
plot. Bivariate scatter plots each have a
fitted line in red. *P<0.05. BMI, body mass
index; PSA, prostate-specific antigen.

Chemotaxis assays on patient urine samples

Prior to use in chemotaxis assays, urine samples were thawed at room
temperature and inverted three times before being freshly diluted in sterile
Milli-Q filtered water. The same diluted sample was used for all replicates
performed on the same day. We first determined the optimal urine dilution
that can distinguish cancer from controls by performing chemotaxis assays
on serially diluted urine at 1:10, 1:50, 1:100, 1:500, and 1:1000 dilutions.
For these assays, the same four patients per group were used for all five
dilutions. We considered the best urine dilution to have the highest overall
Table 2. Classification performance using CI/PSA alone or in
combination for PAC cohort

Accuracy
Balanced Accuracy
Sensitivity
Specificity
Positive predictive value
Negative predictive value
P-value [Acc>NIR]a
P value [Acc>NIR] summarya,b
Mcnemar’s test P-value
Mcnemar’s test summaryb
a

CI Only

PSA Only

PSA+CI

70%
72%
76%
67%
52%
86%
0.45
ns
0.044
*

71%
77%
95%
59%
54%
96%
0.25
ns
4e-4
***

81%
78%
71%
85%
71%
85%
9e-3
**
1
ns

One-sided binomial test; Acc, Accuracy; NIR, no information rate.
ns, not significant; *P<0.05; **P<0.01; ***P<0.001.

b

accuracy rate for discriminating cancer versus control samples, based on a
positive or negative CI, and the highest mean difference between CI when
comparing cancer and control groups. Following determination of the best
urine dilution, we performed chemotaxis assays for the remaining urine
samples only at that dilution. Each round of chemotaxis assays included six
samples assayed at the same time: one unblinded sample from each of the
three groups (negative screen, benign, and cancer) and three samples with
blinded disease status. The disease status of the blinded samples was
revealed following completion of all assays. In some cases, more than six
chemotaxis assay technical replicates were performed in total for some
unblinded samples. To prevent skewed oversampling of these individuals,
six CI technical replicates were randomly sampled and those six CIs were
used to calculate the average CIs for the individuals. Therefore, four to six
chemotaxis assay CIs are averaged to calculate one CI per patient sample
(i.e. biological replicate). As a positive control, at least three chemotaxis
assay replicates using the known attractant isoamyl alcohol (TCI, I0289,
>99.0% purity) as a sample were performed alongside urine sample assays
for each assay block (Bargmann et al., 1993). The isoamyl alcohol was
diluted to 9.09 mM prior to use.
Data analysis

Statistical analysis, subsampling, and plot generation was conducted using
R (v.3.6.1) and Rstudio (v.1.2.5019). For each patient sample, CI replicates
were averaged prior to statistical analysis. CI and clinical data were tested for
normality using the Shapiro–Wilk test with the null hypothesis that the data
are normally distributed ( parametric). Differences in nematode chemotactic
response to urine types (negative screen, benign disease, or prostate cancer)
were determined using a one-way ANOVA. Following a statistically
significant one-way ANOVA, pairwise differences between group means
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dilution prepared in water were performed identically to the urine
chemotaxis assays.
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Fig. 6. Chemotaxis assay plate setup. Diluted sample was placed on the
black dots in T1 and T2 quadrants. Sample diluent (water) was placed on
the black dots in C1 and C2 quadrants. Approximately 50 young adult stage
nematodes were placed in the center circle and allowed to migrate for 1 h.
The plate was then photographed and nematodes in each quadrant were
recorded.

were determined post hoc using Tukey’s HSD test (α=0.05). To test for
differences in CI means between two groups categorized by clinical data, a
Welch two sample t-test was used. For clinical attribute comparisons
between groups, one-way ANOVAs were applied to parametric clinical data,
the Kruskal–Wallis rank sum test was applied to non-parametric clinical data,
and Pearson’s Chi-square test was applied to categorical. Classification model
performance was evaluated using the coin R package and default parameters
(Hothorn et al., 2006). Correlations and line fitting using clinical data were
performed with the PerformanceAnalytics R package (Peterson et al., 2014).
P-values were adjusted for multiple comparisons and statistical significance
was determined at P<0.05 for all tests. Plots were generated using the ggplot2
R package (Wickham, 2016) For boxplots, potential outliers were determined
using the default parameters in the ggplot2 package.
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